Dallah Healthcare Company announces recent developments related to the sale of its shares in Dr. Mohammed Bin Rashed Al Fagih & Partners Company for a value of SAR 497,983,407

Element List	Explanation
Introduction	With reference to the announcement made by Dallah Healthcare Company (“Dallah Healthcare”) on the Saudi Exchange website on 19/11/1447H (corresponding to 06/05/2026G) regarding the entry into a binding share sale and purchase agreement with Dr. Soliman Abdel Kader Fakeeh Hospital Co. (the “Buyer” or “Soliman Fakeeh Co.”) to sell Dallah Healthcare’s entire shareholding of approximately 31.21% in Dr. Mohammed bin Rashid Al Fagih & Partners Company (the “Target” or “Mohammed AlFagih Co.”) (the “Transaction”), and with reference to the subsequent announcement made by Dallah Healthcare on 28/12/1447H (corresponding to 14/06/2026G) regarding the issuance of the non-objection of the General Authority for Competition on the completion of the economic concentration resulting from the Transaction; Dallah Healthcare is pleased to announce that the Transaction has completed on Monday 06/02/1448H (corresponding to 20/07/2026G) after the fulfillment of its conditions, and that the shares in Mohammed AlFagih Co. were transferred from Dallah Healthcare to the Buyer, and that the cash consideration has been paid by the Buyer to Dallah Healthcare.
Previous Announcement	The issuance of the non-objection of the General Authority for Competition on the completion of the economic concentration resulting from the Transaction.
Date of Previous Announcement on Saudi Exchange’s Website	2026-06-14 Corresponding to 1447-12-28
Hyperlink to the Previous Announcement on the Saudi Exchange Website	Click Here
Latest Developments Of The Announced Event	The completion of the Transaction on Monday 06/02/1448H (corresponding to 20/07/2026G) after the fulfillment of its conditions, the transfer of the shares in Mohammed AlFagih Co. from Dallah Healthcare to the Buyer, and the payment of the cash consideration by the Buyer to Dallah Healthcare. An amount of SAR 466,774,106.13 was paid to Dallah Healthcare Company. As disclosed in the announcement regarding the execution of the transaction agreement dated 19/11/1447H (corresponding to 06/05/2026G), a specified portion of the total cash consideration, amounting to SAR 100 million (of which Dallah is entitled to 31.21%), has been placed in an escrow account to cover any breaches or issues that may be discovered in the Target following completion of the Transaction, for a term of six months (or any longer period until the dispute is resolved, if any).
Reasons For The Delay on The Date of The Event Previously Announced	Not Applicable.
The costs associated with the event, and if they have changed or not with indication of the reasons.	Not Applicable.
Delay consequences on the Company’s financial results	Not Applicable.